{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-125888","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.845295+00:00","generated_at":"2026-06-07T12:39:38.656767+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix prices $100.1M public offering; updates wet AMD trial and cash runway into 2027","bullets":["Priced underwritten public offering of 30.8M shares at $3.25/share for gross proceeds of $100.1M; net proceeds ~$93.6M.","Underwriters granted 30-day option for up to 4.62M additional shares; closing expected Dec 18, 2023.","Submitted SPA amendment to FDA to broaden SOL trial inclusion criteria and test single 450 µg implant; patient enrollment may begin Jan 2024.","Net proceeds plus existing cash expected to fund operations into 2027; additional capital needed for regulatory approval of AXPAXLI."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-125888","json":"https://secwatch.observer/filing/0001104659-23-125888.json","markdown":"https://secwatch.observer/filing/0001104659-23-125888.md","text":"https://secwatch.observer/filing/0001104659-23-125888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/0001104659-23-125888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/tm2332876d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:39:38.656767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a1f59a043bf296f74f13a8ed7b964fc95d3545b","claim":"OCULAR THERAPEUTIX, INC entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at public offering price of $3.25 per share (effective 2023-12-13).","evidence_excerpt":"On December 13, 2023, Ocular Therapeutix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 30,800,000 shares (the “Firm Shares”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/0001104659-23-125888-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters"},{"label":"Value","value":"public offering price of $3.25 per share"},{"label":"Effective","value":"2023-12-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}